Slide 1: Q1 2025 Results
Q1 2025 Results Matthias Gaertner, CEO Falk Neukirch, CFO May 13, 2025
Slide 2: Agenda: Executive summary, Financial overview, Guidance, AGM, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2025 4 AGM 2025 “We are creating the leading 5 Appendix European Specialty Pharma platform to treat diseases optimally with individualized medicine.” Matthias Gärtner, CEO Medios AG 2
Slide 3: Highlights Q1 2025 and onwards
Executive summary Highlights Q1 2025 and onwards Good start to fiscal year 2025: Significant increase in profitability, organic EBITDA pre growth in Q1 • Revenue +6.2% to €484.7m Financials • Disproportionate EBITDA pre increase to €23.1m (+52.9%); significant EBITDA pre margin expansion to 4.8%; 4.
Slide 4: QoQ – Revenue and EBITDA pre growth
Executive summary QoQ – Revenue and EBITDA pre growth Revenue (€m) EBITDA pre¹ (€m) 24.6 493 485 490 23.2 23.1 483 441 456 451 431 422 17.2 16.1 15.0 15.1 14.1 14.3 4.8% EBITDA 5.0 4.8 4.8 pre1 3.5 3.3 3.5 3.2 3.3 3.6 margin Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2023 2024 2025 2023 2
Slide 5: YoY Q1 2025 – Strong disproportionate EBITDA pre growth
Executive summary YoY Q1 2025 – Strong disproportionate EBITDA pre growth Revenue in €m EBITDA pre¹ in €m 6.2% 52.9% 23.1 485 456 15.1 EBITDA pre1 4.8% margin 3.3% Q1 2024 Q1 2025 Q1 2024 Q1 2025 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBIT
Slide 6: Agenda: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2025 4 AGM 2025 5 Appendix 6
Slide 7: Q1 2025 – Solid Group financials
Financial overview Q1 2025 – Solid Group financials In € million Q1 2025 Q1 2024 ∆ in % Comments Revenue 484.7 456.2 6.2% Financials including the strong contribution of Ceban (segment International Business “IB”) Gross profit1 49.8 27.6 80.0% gross margin in % 10.3% 6.1% 4.2ppt Revenue growth of 6.
Slide 8: Q1 2025 – Revenue growth driven by International Business
Financial overview Q1 2025 – Revenue growth driven by International Business YoY Revenue in €m Q1 24 Organic Inorganic Q1 25 Comments Pharmaceutical Supply (PS) 401.0 -11.8 - 389.2 • Inorganic growth attributable to Ceban acquisition Patient-Specific Therapies (PST) 55.1 0.7 - 55.8 International Bus
Slide 9: Q1 2025 – Strong EBITDA pre growth driven by all segments
Financial overview Q1 2025 – Strong EBITDA pre growth driven by all segments YoY EBITDA pre1 in €m Q1 24 Organic Inorganic Q1 25 Comments Pharmaceutical Supply (PS) 11.0 0.8 - 11.8 • Successful integration of Ceban; EBITDA pre1 contribution of €7.3m Patient-Specific Therapies (PST) 5.9 0.4 - 6.3 • S
Slide 10: Q1 2025 – Substantial disproportionate EBITDA pre increase
Financial overview Q1 2025 – Substantial disproportionate EBITDA pre increase Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million Q1 25 Q1 24 Q1 25 Q1 24 Q1 25 Q1 24 Q1 25 Q1 24 Q1 25 Q1 24 Q1 25 Q1 24 Segment rev
Slide 11: Status Debt financing
Financial overview Status Debt financing • New financing structure concluded in Nov 2024 : €225m, thereof • €125m as term loan, term: 5 yrs, repayment started in March 2025; €6.25m, annually €25m and • €100m as Revolving credit facility (RCF), term 5 (+1 +1) yrs plus • RCF step up option of further
Slide 12: Guidance 2025
1 Executive summary 2 Financial overview 3 Guidance 2025 4 AGM 2025 5 Appendix “Medios delivers the best quality – reliably, competently and fast. These are key criteria for the optimal care of our patients.” 12
Slide 13: Disproportionate EBITDA pre increase expected
Guidance 2025 & growth story Disproportionate EBITDA pre increase expected Revenue (€bn) EBITDA pre1(€m) + 6.0% ~2.0 ~96 1.9 + 21.5% 79 Margin ~4.8 (%) 4.2 2024 2025E* 2024 2025E* 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjust
Slide 14: AGM 2025
1 Executive summary 2 Financial overview 3 Guidance 2025 4 AGM 2025 5 Appendix “Medios delivers the best quality – reliably, competently and fast. These are key criteria for the optimal care of our patients.” 14
Slide 15: ITEM 7: Compensation system for the Management Board
ITEM 7: Compensation system for the members of the Management Board Realignment of the Short-Term Incentive (STI) New financial KPI: Operative Cash Flow – Replacing the M&A component • Objective: stronger focus on operational performance indicators • Promotion of efficiency, profitability, and liqui
Slide 16: ITEM 7: Compensation system for the Management Board
ITEM 7: Compensation system for the members of the Management Board Realignment of the Short-Term Incentive (STI) • New STI Structure as of 2025 KPI Old weighting New weighting ➢ Inorganic growth (M&A) 40% Replaced ➢ Revenue Growth 20% 20% (unchanged) ➢ EBITDA pre Growth 20% 30% (+10%) ➢ EBITDA pre
Slide 17: ITEM 8: Creation of a new SOP 2025 and Conditional Capital 2025/I
ITEM 8: Creation of a new SOP 2025 and a new Conditional Capital 2025/I Creation of Stock Option Plan 2025 (SOP 2025) • Volume: total of 899,697 subscription rights • Allocation among beneficiaries • Executive Board of Medios AG: up to 320,000 • Employees and executives of Medios AG: up to 219,697 •
Slide 18: ITEM 9: New authorization to issue convertible bonds
ITEM 9: New authorization to issue convertible bonds with the possibility of excluding of subscription rights • Creation of new authorization to issue convertible bonds until May 26, 2030, with the possibility to exclude shareholder subscription rights (simplified exclusion of subscription rights) a
Slide 19: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2025 4 AGM 2025 5 Appendix “I work for Medios because I can contribute to patient care that meets the highest quality standards.” 19
Slide 20: Synergistic positions across the compounding value chain
Appendix Synergistic positions across the compounding value chain Compounding Services API Services Pharmacies • Tailor-made medication • Sourcing, repacking and • 23 owned pharmacies across compounded at GMP-compliant distributing APIs and excipients the Netherlands under the facilities for pharmac
Slide 21: ESG highlights 2024
Appendix ESG highlights 2024 Proportion of women 69% in workforce 0.1% Customer 47% complaint rate in management 1,208 t CO2e 64% Share of green Scope 1 & 2 electricity emissions in Germany Offset (c. -16% vs. 2023) t CO2e tonnes of CO2-equivalents | MWh Megawatt hours 21
Slide 22: Average to above-average ESG Ratings
Appendix Average to above-average ESG Ratings 0 57 100 Exceeds the industry benchmark of 42% D– C– A+ Top 15% in the Industry CCC AAA AA Top 43% in the Industry 0 100 34 Top 50% universe ranking 100 0 39 100 Top 13% in the Industry 100 13.6 0 Top 6% in the Industry (low risk) Source: Reports of resp
Slide 23: Key figures (1/2)
Appendix Key figures (1/2) in € thousand Q1 2025 Q1 2024 ∆ in % Revenue 484,657 456,224 6.2% Pharmaceutical Supply 389,236 401,042 -2.9% Patient-Specific Therapies 55,762 55,061 1.3% International Business 39,543 0 n/a Services 116 121 -4.1% EBITDA 21,762 11,733 85.5% Margin (in % of Revenue) 4.5% 2
Slide 24: Key figures (2/2)
Appendix Key figures (2/2) in € thousand Q1 2025 Q1 2024 ∆ in % Earnings per share (in €) Undiluted 0.25 0.17 47.1% Diluted 0.25 0.17 47.1% Investments (CAPEX) 1,247 466 >100.0% Cash flow from operating activities 3,563 43,385 -91.8% Free cash flow2 (before M&A) 2,316 42,919 -94.6% Extraordinary exp
Slide 25: Proposed Remuneration System for the Executive Board
Appendix Proposed Remuneration System for Total target remuneration the Executive Board ESG Compensation structure of the total target remuneration Non-performance related fixed remuneration 28 – 35% Performance related remuneration 65 – 72% 1. Annual Short-Term-Incentive (STI) (target: 100%) 28 – 3
Slide 26: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 claudia.nickolaus@medios.group
Slide 27: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 28: Q1 2025 Results
Q1 2025 Results Matthias Gaertner, CEO Falk Neukirch, CFO May 13, 2025